Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 172, Issue 2, Pages 262-273Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.13827
Keywords
romiplostim; immune thrombocytopenia; thrombopoietin receptor agonist; platelet response; remission
Categories
Funding
- Amgen Inc. [NCT01143038, 20080435]
Ask authors/readers for more resources
In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet counts after discontinuing romiplostim. Here, we examined rates of platelet response (50x10(9)/l), remission, splenectomy and adverse events in patients with primary ITP duration 6months who were treated with romiplostim for 12months. The starting dose of romiplostim was 1g/kg; concomitant and rescue treatments were permitted to maintain platelet counts. Patients with platelet counts 50x10(9)/l at the end of 12months entered a dose taper in which the romiplostim dose was decreased as long as platelet counts were maintained. Remission (platelet count 50x10(9)/l for 24 consecutive weeks with no ITP treatments) was evaluated in patients once romiplostim was discontinued. Over the 12months, a high response rate (>90%) was observed. Platelet response occurred quickly (median, similar to 2weeks) and was observed for a cumulative median of 11months. Remission was observed in 24 patients (32%); there were no significantly predictors of remission. Most (20/24) patients had remission start before the forced taper. No new safety signals were identified. Thus, in patients with early-stage ITP, romiplostim was well tolerated and induced rapid responses, with remission occurring in approximately one-third of patients (NCT01143038, Amgen 20080435).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available